GS-7977 is definitely no white elephant rgc68 but at the same time doesn't appear to be a silver bullet either.
Judging by the price paid by Gilead i think that they believed they would corner the market.Despite the calm external demeanor I would imagine there would be some nerves internally.Wether Biotron can lever off any uncertainty remains to be seen.
The more I learn about the HepC market the less I know...but the door still looks open.GL Holders.
updated findings on gilead trial on g1 patient, page-9
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
